Patient disposition
| . | Venetoclax 400 mg (14 d/cycle) + azacitidine 75 mg/m2 (7 d/cycle) N = 107 . |
|---|---|
| Remain on study treatment, n (%) | 6 (5.6) |
| Discontinued treatment, n (%) | 101 (94.4) |
| Primary reason for discontinuation, n (%) | |
| Transplant | 40 (37.4) |
| Progressive disease | 26 (24.3) |
| Physician decision | 14 (13.1) |
| AEs | 10 (9.3) |
| Withdrawal of consent | 5 (4.7) |
| Death | 3 (2.8) |
| Other | 3 (2.8) |
| . | Venetoclax 400 mg (14 d/cycle) + azacitidine 75 mg/m2 (7 d/cycle) N = 107 . |
|---|---|
| Remain on study treatment, n (%) | 6 (5.6) |
| Discontinued treatment, n (%) | 101 (94.4) |
| Primary reason for discontinuation, n (%) | |
| Transplant | 40 (37.4) |
| Progressive disease | 26 (24.3) |
| Physician decision | 14 (13.1) |
| AEs | 10 (9.3) |
| Withdrawal of consent | 5 (4.7) |
| Death | 3 (2.8) |
| Other | 3 (2.8) |